The company is planning to apply an algorithm that is based on one of its core technologies called AlphaGo — software that beat top human players in a strategy game called Go — to ultimately build drugs.
What’s more, the technology needed to fold the proteins doesn’t require the same computing power of the version that beat the world champion Go player. Instead, researchers are basing their healthcare application off AlphaGo Zero, which used one-twelfth of the power of AlphaGo.
Unlike AlphaGo, AlphaGo Zero learned from scratch how to play the game. DeepMind’s latest project is using these same algorithmic principles in protein folding, a crucial step for drug discovery.
“It is the novel algorithms that really matter,” David Silver, PhD, the principal investigator on DeepMind’s Go project, told Bloomberg. “It is actually the algorithmic advances that lead to more progress than either compute power or data.”
More articles on artificial intelligence:
Massachusetts General uses machine learning tool to predict breast cancer
53% of CIOs say machine learning is a key focus in their digitization efforts
Huawei, Philips integrate cloud AI to healthcare project
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
